公开(公告)号：EP1644858B1

公开(公告)日：2017-12-06

申请号：EP04777383.3

申请日：2004-06-30

申请人： Genomic Health, Inc. ,  NSABP Foundation, Inc.

发明人： BAKER, Joffre ,  BRYANT, John, L. ,  PAIK, Soonmyung ,  SHAK, Steven

IPC分类号： G06F19/00 ,  C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N33/57484 ,  G01N33/57492 ,  G06F19/20 ,  G06F19/24

摘要： The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk.

公开(公告)号：EP1815014B1

公开(公告)日：2012-03-21

申请号：EP05821698.7

申请日：2005-11-04

申请人： Genomic Health, Inc. ,  NSABP Foundation, Inc.

发明人： BAKER, Joffre, B. ,  BRYANT, John, L. ,  PAIK, Soonmyung ,  SHAK, Steven

IPC分类号： C12Q1/68 ,  G01N33/574 ,  C12N15/10

CPC分类号： G01N33/57415 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  G06F19/18 ,  G06F19/20

摘要： The present invention relates to quantitative molecular indicators that can guide clinical decisions in breast cancer, such as estrogen receptor (ESR1)-positive, lymph node-negative breast cancer. In particular, the invention concerns certain genes, the varied expression of which indicates the likelihood of recurrence of surgically resected breast cancer in patients who are not treated with a therapeutic agent in the adjuvant setting. In addition, the invention concerns the use of quantitative measurement of the expression of certain genes, including the ESR1 gene, that measures as a continuous variable, to determine (a) the likelihood of a beneficial response to the anti-estrogen therapeutic agent, such as tamoxifen; and (b) the potential magnitude of beneficial response to chemotheraphy.

公开(公告)号：EP1815014A2

公开(公告)日：2007-08-08

申请号：EP05821698.7

申请日：2005-11-04

申请人： Genomic Health, Inc. ,  NSABP Foundation, Inc.

发明人： BAKER, Joffre, B. ,  BRYANT, John, L. ,  PAIK, Soonmyung ,  SHAK, Steven

IPC分类号： C12Q1/68 ,  G01N33/574 ,  C12N15/10

CPC分类号： G01N33/57415 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  G06F19/18 ,  G06F19/20

摘要： The present invention relates to quantitative molecular indicators that can guide clinical decisions in breast cancer, such as estrogen receptor (ESR1)-positive, lymph node-negative breast cancer. In particular, the invention concerns certain genes, the varied expression of which indicates the likelihood of recurrence of surgically resected breast cancer in patients who are not treated with a therapeutic agent in the adjuvant setting. In addition, the invention concerns the use of quantitative measurement of the expression of certain genes, including the ESR1 gene, that measures as a continuous variable, to determine (a) the likelihood of a beneficial response to the anti-estrogen therapeutic agent, such as tamoxifen; and (b) the potential magnitude of beneficial response to chemotheraphy.

公开(公告)号：EP1836629B1

公开(公告)日：2020-03-04

申请号：EP05817266.9

申请日：2005-11-04

申请人： Genomic Health, Inc. ,  NSABP Foundation, Inc.

发明人： BAKER, Joffre, B. ,  BRYANT, John, L. ,  PAIK, Soonmyung ,  SHAK, Steven

IPC分类号： G16B20/00 ,  C12Q1/6886 ,  G16B25/00

公开(公告)号：EP3330875A1

公开(公告)日：2018-06-06

申请号：EP17205130.2

申请日：2004-06-30

申请人： Genomic Health, Inc. ,  NSABP Foundation, Inc.

发明人： BAKER, Joffre ,  BRYANT, John, L. ,  PAIK, Soonmyung ,  SHAK, Steven

IPC分类号： G06F19/00 ,  C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N33/57484 ,  G01N33/57492 ,  G06F19/20 ,  G06F19/24

摘要： The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk.

公开(公告)号：EP1836629A1

公开(公告)日：2007-09-26

申请号：EP05817266.9

申请日：2005-11-04

申请人： Genomic Health, Inc. ,  NSABP Foundation, Inc.

发明人： BAKER, Joffre, B. ,  BRYANT, John, L. ,  PAIK, Soonmyung ,  SHAK, Steven

IPC分类号： G06F19/00 ,  C12Q1/68

摘要： The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i) Recurrence Score, (ii) ESRI Group Score; (iii) Invasion Group Score; (iv) Proliferation Group Score; and (v) the expression level of the RNA transcript of at least one of MYBL2 and SCUBE2, or the corresponding expression product. The invention further comprises a molecular assay-based algorithm to calculate the likelihood that the patient will have a beneficial response to chemotherapy based on the risk score.

公开(公告)号：EP1644858A2

公开(公告)日：2006-04-12

申请号：EP04777383.3

申请日：2004-06-30

申请人： Genomic Health, Inc.

发明人： BAKER, Joffre ,  BRYANT, John, L. ,  PAIK, Soonmyung ,  SHAK, Steven

IPC分类号： G06F19/00 ,  C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N33/57484 ,  G01N33/57492 ,  G06F19/20 ,  G06F19/24

摘要： The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk.